Skip to main content
. 2016 Sep 7;20(6):551–557. doi: 10.1007/s40291-016-0232-1
Genetic variants of Rac1 and NCF2 are identified as susceptibility single nucleotide polymorphisms for IBD.
The immunosuppressive mechanism of thiopurine treatment relies on the modification of Rac1.
Rac1 may serve as a potential biomarker to predict (pharmacological) effectiveness of thiopurine therapy.